Many cancer vaccines have been studied, but thus far the search has been unsuccessful. Results from a new study suggest that the combination of a messenger (mRNA)-based personalized cancer vaccine (known as RO7198457) plus the PD-L1 inhibitor atezolizumab (Tecentriq) shows promise for the treatment of advanced cancer.
A real-world analysis showed that adjuvant immunotherapy in patients with stage III melanoma improved survival, but that only approximately 33% of eligible patients received such adjuvant therapy after ipilimumab (Yervoy) was approved by the FDA for this indication.
“COVID-19 is more than just the common cold. It represents a perpetual challenge for which we have to be perpetually prepared,” stated Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), in his keynote lecture at the July 2020 AACR virtual meeting on COVID-19 and cancer. Dr Fauci has been Director of NIAID for 36 years.
During the July 2020 AACR virtual meeting on COVID-19 and cancer, Solange Peters, MD, PhD, European Society for Medical Oncology President, and Head, Medical Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, delivered the keynote address, providing an update on the COVID-19 and Cancer Consortium cohort study.
One question on oncologists’ minds recently is whether treatment with immune checkpoint inhibitors in patients with cancer has a negative effect on COVID-19 disease. So far, the data have not shown a deleterious effect, but the definitive answer is unknown.
The addition of the checkpoint inhibitor atezolizumab (Tecentriq) to the 2 targeted therapies—the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib (Cotellic)—improved progression-free survival (PFS) and the duration of responses compared with the 2 targeted therapies plus placebo in patients with newly diagnosed advanced melanoma and BRAF V600E/K mutation, according to the phase 3 IMspire150 clinical trial.
Tumors with KRAS mutation are notoriously difficult to treat. Early data presented at the 2020 American Association for Cancer Research virtual annual meeting suggest 2 new routes for the treatment of cancers with KRAS mutation, including (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) the use of onvansertib, an investigational competitive inhibitor of the PLK1 enzyme, together with chemotherapy.
At the 2020 virtual American Association for Cancer Research (AACR) annual meeting, part I, a team of oncologists from different COVID-19 hotspots around the world gave a snapshot of wisdom gleaned from their experience thus far.
Bispecific CAR T-Cells Show Promise in Children and Young Adults with Relapsed B-Cell Acute Lymphoblastic Leukemia
A bispecific chimeric antigen receptor (CAR) T-cell product directed against CD19 and CD22 antigens induced a complete response (CR) in 5 of 12 (42%) evaluable children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL).
Data from the TRACERx lung study suggest that circulating tumor DNA (ctDNA) may be a biomarker for the detection of postsurgical minimal residual disease (MRD) in patients with non–small-cell lung cancer (NSCLC), suggesting which patients are at increased risk for disease relapse and will require more aggressive adjuvant therapy.
Page 1 of 2
Results 1 - 10 of 12
Results 1 - 10 of 12